February 26, 2018 / 9:36 PM / 7 months ago

BRIEF-Lilly Receives Additional FDA Approval For Verzeniotm, As Initial Treatment For Advanced Breast Cancer

Feb 26 (Reuters) - Eli Lilly And Co:

* LILLY RECEIVES ADDITIONAL FDA APPROVAL FOR VERZENIOTM (ABEMACICLIB), AS INITIAL TREATMENT FOR ADVANCED BREAST CANCER

* ELI LILLY AND CO - ‍NEW INDICATION BASED ON MONARCH 3 TRIAL CAN HELP MORE WOMEN LIVING WITH HR+, HER2- ADVANCED BREAST CANCER​

* ELI LILLY - ‍RECOMMENDED DOSE OF VERZENIO IN COMBINATION WITH AI IS 150 MG ORALLY TWICE DAILY, CONTINUED UNTIL DISEASE PROGRESSION/ UNACCEPTABLE TOXICITY​

* ELI LILLY AND CO - ‍VERZENIO IS AVAILABLE IN 4 TABLET STRENGTHS (200 MG, 150 MG, 100 MG, AND 50 MG)​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below